Triple negative breast cancer wreaks a particularly heavy toll in certain regions and populations, with stark differences in both incidence and survival rates across geographical lines. Recent studies ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has become the first drug to outperform chemotherapy in immunotherapy-ineligible metastatic ...

New longer-term results show a survival benefit from adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to first-line chemotherapy for women with metastatic triple-negative breast cancer ...

Sacituzumab govitecan targets Trop-2 and delivers potent chemo directly to TNBC cells. PARP inhibitors are effective in TNBC patients with BRCA mutations. Immune checkpoint inhibitors benefit patients ...

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers, such as PD-L1 expression or ...

Already boasting a strong foothold in metastatic triple-negative breast cancer, Gilead Sciences’ Trodelvy has produced positive data that could make the antibody-drug conjugate part of a new ...

Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer clinical trials in the Asia-Pacific region, and the significant investments ...

New data support integrating tumor-infiltrating lymphocyte levels with nodal status to improve risk stratification in women with triple-negative breast cancer (TNBC) and pathological complete response ...

DelveInsight’s, “Triple Negative Breast Cancer Pipeline Insight” report provides comprehensive insights about 75+ companies ...

This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024. Fast Track Designation for LP-184 recognizes TNBC as a ...